Abstract: The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by JAK2, CALR, and MPL mutations has become a focus for the development of targeted therapies for patients with MPN. JAK2 inhibitors now represent a standard of clinical care for certain forms of MPN […]
New FDA Approved Treatment for Polycythemia Vera Patients are Asking – MPN ExpertDr. Abu-Zeinah discussesRopeginterferon, FDA ApprovedTreatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat Polycythemia Vera. Patients are asking: Should I switch from Pegasys to the new FDA approved Ropeginterferon? How might Ropeginterferon change […]
by Lou Ann Donovan We all enjoy getting together with friends and attending family gatherings from time to time. Such occasions give us an opportunity to catch up, share ideas, and even lend support to each other. Social connections like these also influence our health and longevity the same as our diet, sleep, and exercise. […]
by Lou Ann Donovan Stress and the Body Stress is a natural physical and mental response to life experiences. Some stress is even good and can trigger a fight or flight response to help you handle emergencies. However, even the stressful events are not what causes the harm. It is our reaction to the challenges […]
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials and new drugs in development for 2021 and beyond. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a […]
Episode 1 of 3 in Patients are Asking Series Episode 1 of 3 What symptoms should I look for to see if I might be progressing from polycythemia vera to myelofibrosis? When would you typically recommend Next Generation Sequencing (NGS) and what are the benefits? Why does bone & joint pain occur and what are some […]
Abstract: Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are clonal hematological diseases classified as Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). MPN pathogenesis is associated with the presence of somatic driver mutations, bone marrow (BM) niche alterations, and tumor inflammatory status. The relevance of soluble mediators in the pathogenesis of MPN led us […]
Abstract CALR mutations are a revolutionary discovery and represent an important hallmark of myeloproliferative neoplasms (MPN), especially essential thrombocythemia and primary myelofibrosis. To date, several CALR mutations were identified, with only frameshift mutations linked to the diseased phenotype. It is of diagnostic and prognostic importance to properly define the type of CALR mutation and subclassify it according to […]
by Lou Ann Donovan When you are living with a myeloproliferative neoplasm (MPN), fatigue is the most frequent symptom discussed among fellow patients. One minute you are feeling great then suddenly you feel so tired that you need to take a nap. Dealing with constant fatigue can affect your ability to complete daily tasks such […]
by Lou Ann Donovan Are you searching for an MPN clinical trial and wondering what all these acronyms and abbreviations listed in the trial study details mean? Well, you are probably familiar with the acronym FDA which is for the Food and Drug Administration. Or maybe you have seen the term QC for Quality Check. […]
Site by: Kaleidoscopic
